Trial Profile
A Pilot Study to Evaluate the Effect of CT1812 Treatment on Amyloid Beta Oligomer Displacement Into CSF in Subjects With Mild to Moderate Alzheimer's Disease
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 14 Aug 2023
Price :
$35
*
At a glance
- Drugs CT 1812 (Primary)
- Indications Alzheimer's disease
- Focus Pharmacodynamics
- Acronyms SNAP
- Sponsors Cognition Therapeutics
- 08 Aug 2023 According to a Cognition Therapeutics media release, published confirmatory evidence from this SNAP Study in Translational Neurodegeneration.
- 10 Mar 2022 According to a Cognition Therapeutics media release, the company plans to publish complete Phase 1b SNAP results in a peer-reviewed journal later this year.
- 10 Mar 2022 According to a Cognition Therapeutics media release, data form this trial will be presented at the upcoming AD/PD 2022: the 16th International Conference on Alzheimer's & Parkinson's Diseases.